The weekly litigation news digest is live. Subscribe now

Anavex Life Sciences competitive analysis

Explore Anavex Life Sciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Dec 25, 2025
Patent NumberPublication DateTitleTotal Oppositions

Get instant alerts of patent oppositions faced by Anavex Life Sciences

Nov 20, 2024Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 Receptor1
Aug 17, 2022Neurodevelopmental Disorder Therapy1

Latest PTAB cases involving Anavex Life Sciences

Discover the latest PTAB cases involving Anavex Life Sciences, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Anavex Life Sciences with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Dec 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ANAVEX LIFE SCIENCES - 2 - -
ELKINGTON AND FIFE92 - - -
SANDOZ1201619 -